November 30 (SeeNews) - Bulgarian drug trader Sopharma Trading [BUL:SO5] said that its consolidated net profit, excluding minority interest, fell to 6.3 million levs ($3.7 million/3.2 million euro) in the first nine months of the year from 7.2 million levs in the comparable period of 2017, despite a rise in revenue.
The company's total operating revenue grew to 660.0 million levs in the January-September period from 512.1 million levs in the same period of 2017, Sopharma Trading said in a bourse filing on Thursday.
Total operating expenses increased to 652.2 million levs in the review period from 503.6 million levs a year earlier, following a rise in cost of goods sold.
As at 8:55 CET on Friday, Sopharma Trading shares traded 0.71% lower at 6.95 levs on the Bulgarian Stock Exchange.
Sopharma Trading is a unit of Bulgarian drug maker Sopharma [BUL:3JR].
(1 euro = 1.95583 levs)